Restructuring Expenses

9 Months Ended

Sep. 30, 2020

Restructuring and Related Activities [Abstract]

Restructuring Expenses

Restructuring ExpensesIn the first quarter of 2020, the Company announced a company-wide organizational realignment initiative in order to more effectively align its organizational infrastructure and operations with the strategic vision of the autonomous pharmacy. In the second quarter of 2020, the Company continued its organizational realignment initiative, as well as initiated a restructuring plan to help mitigate the adverse impact of the COVID-19 pandemic on its business and financial results. During the nine

months ended September 30, 2020, the Company incurred and accrued $10.0 million of employee severance costs and related expenses. As of September 30, 2020, the unpaid balance related to this restructuring plan was $1.0 million.

The following table summarizes the total restructuring expense recognized in the Company’s Condensed Consolidated Statements of Operations for the nine months ended September 30, 2020:

		Nine Months Ended September 30, 2020
	(In thousands)
Cost of product and service revenues		$	2,564
Research and development		3,716
Selling, general, and administrative		3,681
Total restructuring expense		$	9,961